Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Computational models for identifying potential P-glycoprotein substrates and inhibitors.

Patrizia Crivori1, Benedetta Reinach, Daniele Pezzetta

  • 1Prediction and Modeling, Preclinical Profiling, Preclinical Development, Nerviano Medical Sciences, viale Pasteur 10, 20014 Nerviano, Italy. patrizia.crivori@nervianoms.com

Molecular Pharmaceutics
|May 12, 2006
PubMed
Summary

Computational models predict P-glycoprotein (P-gp) substrates and inhibitors, crucial for anticancer drug development. These models identify key molecular features to guide the design of new drugs, improving therapeutic outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Genetic Algorithm-Based Approach for Quantitative Prediction of Drug-Drug Interactions Caused by Cytochrome P450 3A Inhibition or Induction in Horses.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Development of an Empirical Approach for the Prediction of Cytochrome P450-Based Drug-Drug Interactions in Pediatric Patients.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

A Randomized Trial on the Combined Effect of Ponesimod and Propranolol on Heart Rate, Cardiac Safety, and Pharmacokinetics in Healthy Adults.

Clinical and translational science·2025
Same author

A genetic algorithm-based approach for quantitative prediction of drug-drug interactions caused by cytochrome P450 3A inhibitors and inducers in dogs and cats.

Chemico-biological interactions·2025
Same author

A genetic algorithm-based approach for the prediction of metabolic drug-drug interactions involving CYP2C8 or CYP2B6.

Journal of pharmacological and toxicological methods·2024
Same author

Pharmacokinetics of intranasal drugs, still a missed opportunity?

Xenobiotica; the fate of foreign compounds in biological systems·2024

Area of Science:

  • Pharmacology
  • Computational Chemistry
  • Drug Discovery

Background:

  • Multidrug resistance via ATP binding cassette (ABC) transporters like P-glycoprotein (P-gp) hinders anticancer drug development.
  • P-gp affects drug absorption, elimination, and blood-brain barrier penetration, necessitating prediction of drug interactions.
  • Identifying P-gp substrates and inhibitors is critical for designing effective and safe drug candidates.

Purpose of the Study:

  • To develop and validate computational models for predicting P-glycoprotein (P-gp) substrates and inhibitors.
  • To identify key molecular features distinguishing P-gp substrates from inhibitors for rational drug design.
  • To integrate these predictive models into virtual screening workflows for drug discovery.

Main Methods:

Related Experiment Videos

  • Development of a computational model using molecular descriptors (Volsurf) and partial least squares discriminant analysis (PLSD) to classify P-gp substrates and nonsubstrates based on Caco-2 permeability data.
  • Validation of the substrate prediction model on an external set of 272 compounds with 72% accuracy.
  • Creation of a second model using GRIND-pharmacophore descriptors and PLSD to differentiate P-gp substrates from inhibitors based on calcein-AM (CAM) assay data and literature, achieving 82% accuracy.

    • Main Results:

    • The first model accurately predicted P-gp substrate/nonsubstrate behavior for 72% of external compounds.
    • The second model successfully discriminated between P-gp substrates and inhibitors with 82% average accuracy.
    • Key molecular features differentiating substrates from inhibitors were identified, offering insights for drug design.

    Conclusions:

    • Two validated computational models can effectively predict P-gp substrate and inhibitor status.
    • These models aid in identifying potential drug candidates that may be affected by P-gp.
    • The identified molecular features provide valuable guidance for designing new anticancer drugs with improved efficacy and reduced P-gp related adverse effects.